Business
electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
Addition of Quell® Platform Broadens electroCore’s Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness MarketsROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (Nasdaq: NURO), positioning itself as a diversified leader in non-in
About this update from Electrocore, Inc.
[{"type":"image","alt":"electroCore, Inc.","displaySize":"","headline":null,"caption":"electroCore, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/7811b7d6996b3bdbba50262f0a2f8b72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uvgACRsMp7ZiIRhie6e7ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7811b7d6996b3bdbba50262f0a2f8b72","width":300,"height":85}},"lazy":false},{"type":"text","content":"Addition of Quell® Platform Broadens electroCore’s Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets","length":145,"tagName":"p"},{"type":"text","content":"ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (Nasdaq: NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions.","length":392,"tagName":"p"},{"type":"text","content":"The acquisition of NeuroMetrix’s Quell® Fibromyalgia Solution expands electroCore’s portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chronic pain and wellness conditions.","length":337,"tagName":"p"},{"type":"text","content":"Dan Goldberger, CEO of electroCore, Inc. commented, "With this transaction now closed, we are well-positioned to immediately leverage our established distribution channels, particularly within the VA Hospital System, to accelerate adoption of the Quell Fibromyalgia solution. This addition meaningfully expands our addressable market and diversifies our portfolio of non-pharmaceutical, non-invasive nerve stimulation offerings, strengthening electroCore’s position as a leading publicly traded bioelectronic technology platform focused on wellness and chronic pain management."","length":588,"tagName":"p"},{"type":"text","content":"Under the terms of the Merger Agreement dated December 17, 2024 and approved by NeuroMetrix’s stockholders at a Special Meeting held on March 21, 2025:","length...